Anatara Lifesciences (ASX:ANR) has released encouraging pre-clinical trial data of its Gastrointestinal ReProgramming (GaRP) dietary supplement which targets diarrhoea.
The company is now targeting the second half of this year for human trials of GaRP which treats underlying causes such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
“Anatara believes its GaRP dietary supplement may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions.
“During pre-clinical development the proprietary formulation has provided strong scientific evidence that it can combat the three underlying causes.”
According to the company the data shows:
# GaRP inhibits the attachment and invasion of pro-inflammatory bacteria in the gut
# It reduces gut inflammation by 85 per cent
# And it promotes mucosal healing.
Anatara’s products are based on Bromelain, a mixture of proteases extracted from pineapple stems.
Specific proteases within Bromelain have anti-attachment, anti-secretory and anti-inflammatory activity.
Anatara’s lead product, Detach, has been registered by the Australian Pesticides and Veterinary Medicines Authority (APVMA) as a treatment for scour in piglets.
Detach’s approved label reads: “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.
GaRP is designed for humans and is administered alongside conventional medications where it has been found not to interfere with their action.
“If this clinically-relevant finding translates into humans, patients will have the advantage of being able to reduce their dose of disease-modifying medications which are renowned for their devastating side effects such as sepsis.”
Subscribe to our free @AuManufacturing newsletter here.